News

Launched in India in 1980, Little’s is present across a wide range of products including – baby feeding bottles, baby skin-care, baby grooming accessories, baby apparels and baby

This action follows the earlier inspections of these sites by the agency in November 2014, January 2015 and February 2015, respectively. Dr. Reddy’s CEO G V Prasad said:

Additionally, Agenus obtained an exclusive license to a phage display library from IONTAS, and entered into an agreement for cell line development technology with Selexis. These new capabilities,

MD Anderson will leverage its expertise in developing allogeneic umbilical cord blood and peripheral blood derived NK-cell therapies and combine it with CytomX’s Probody technology to address new

Sotagliflozin (LX4211) is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for diabetes patients.

JKB-122 is a TLR4 (Toll-like Receptor 4) antagonist on patients with AIH who are refractory to or intolerant to the existing standard of care (SOC). Duke Clinical Research

Under the PAZOFOS randomized, controlled clinical study, OxiGENE plans to enroll up to 128 patients at up to ten sites in the UK. It includes a phase 1b

The company plans to extend the existing indication for Opdivo to include the treatment of adult patients with advanced RCC after prior therapy. Validation confirms that the application

Genvoya, a combination tablet approved as a complete regimen, is designed to treat earlier untreated patients weighing about 35 kilograms. It features elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.